Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 106

Sort by

Sort Order Select

Journal Articles

AML-MR Mutations Drive the Benefit of CPX-351 over 7+3 in the Pivotal Phase 3 AML Trial

Shai O. Shimony, Heardley Murdock, Julia Keating, Christopher R. Reilly, Harrison K. Tsai, Christopher J. Gibson, Stefan Faderl, Tony Wagner, Nalina Dronamraju, Tara L. Lin, Ellen K. Ritchie, Thomas Prebet, Jorge E. Cortes, Geoffrey L. Uy, Jeffrey E Lancet, Donna S. Neuberg, Richard M. Stone, R. Coleman Lindsley

Blood (2024) 144 (Supplement 1): 60.

https://doi.org/10.1182/blood-2024-200413

Published: 2024

Journal Articles

Intensive Chemotherapy (IC) Followed By Oral Azacitidine (AZA) Maintenance Versus Venetoclax (VEN) Plus AZA for Patients (pts) with Acute Myeloid Leukemia (AML): Retrospective Analysis of an Electronic Medical Record (EMR) Database in the United States

Alice Mims, Zhuoer Xie, Alberto Vasconcelos, Maria Strocchia, Lona Gaugler, Sara Vergara, Ying Qiu, David Rotter, Ravi Potluri, Thomas Prebet, Jan Sieluk

Blood (2023) 142 (Supplement 1): 550.

https://doi.org/10.1182/blood-2023-173442

Published: 2023

Journal Articles

Efficacy and Safety of Luspatercept Versus Epoetin Alfa in Erythropoiesis-Stimulating Agent (ESA)-Naive Patients (Pts) with Transfusion-Dependent (TD) Lower-Risk Myelodysplastic Syndromes (LR-MDS): Full Analysis of the COMMANDS Trial

Blood (2023) 142 (Supplement 1): 193.

https://doi.org/10.1182/blood-2023-178596

Published: 2023

Journal Articles

Clonal Dynamics of Gene Mutations during Oral Azacitidine Maintenance Therapy in Patients with Acute Myeloid Leukemia (AML): Outcomes from the QUAZAR AML-001 Trial

Daniel Lopes De Menezes, Manuel Ugidos Guerrero, Arnaud Amzallag, Wendy L. See, Alberto Risueno, Charalampos Kyriakopoulos, Rajasekhar N.V.S. Suragani, Barry S. Skikne, C.L. Beach, Thomas Prebet, Maria Teresa Voso, Andre C. Schuh, Gail J. Roboz, Hartmut Döhner, Andrew H. Wei, Anita K. Gandhi

Blood (2023) 142 (Supplement 1): 1582.

https://doi.org/10.1182/blood-2023-187651

Published: 2023

Journal Articles

Survival Outcomes for Patients in the QUAZAR AML-001 Trial Who Received Subsequent Therapy for Acute Myeloid Leukemia (AML) after Discontinuing Oral Azacitidine or Placebo

Farhad Ravandi, Pau Montesinos, Michael Pfeilstöcker, Cristina Papayannidis, Hervé Dombret, Yinzhi Lai, Erica Petrlik, Thomas Prebet, Hartmut Döhner

Blood (2022) 140 (Supplement 1): 3277–3279.

https://doi.org/10.1182/blood-2022-159045

Published: 2022

Journal Articles

Molecular Features Associated with Response to Combination Therapy with Enasidenib (ENA) Plus Azacitidine (AZA) in Newly Diagnosed IDH2 -Mutated Acute Myeloid Leukemia (AML)

Alberto Risueño, Wendy L. See, Courtney D. DiNardo, Hartmut Döhner, Eytan Stein, Amir T. Fathi, Paresh Vyas, Lynn Quek, Thomas Prebet, Anita K. Gandhi, Maroof Hasan

Blood (2022) 140 (Supplement 1): 732–734.

https://doi.org/10.1182/blood-2022-158967

Published: 2022

Journal Articles

Olutasidenib (FT-2102) in Combination with Azacitidine Induces Durable Complete Remissions in Patients with mIDH1 Acute Myeloid Leukemia

Blood (2021) 138 (Supplement 1): 698.

https://doi.org/10.1182/blood-2021-144905

Published: 2021

Journal Articles

Implementation of Inpatient Palliative Care Consultation Triggers and Its Impact on Healthcare Use in Patients with Relapsed/Refractory Acute Myeloid Leukemia

Jenny J Xiang, Elizabeth Horn Prsic, Kerin B Adelson, Thomas Prebet

Blood (2021) 138 (Supplement 1): 3018.

https://doi.org/10.1182/blood-2021-149300

Published: 2021

Journal Articles

Characteristics and Clinical Outcome of Patients with Clonal Cytopenias of Undetermined Significance: A Large Retrospective Multi-Center International Study

Blood (2021) 138 (Supplement 1): 2158.

https://doi.org/10.1182/blood-2021-146254

Published: 2021

Journal Articles

Trial in Progress: Glad-AML - a Randomized, Phase 2 Trial of Glasdegib with Two Standard Decitabine Regimens for Older Patients with Newly-Diagnosed, Poor-Risk Acute Myeloid Leukemia

Rory M. Shallis, MD, Nikolai A. Podoltsev, MD PhD, Thomas Prebet, MD PhD, Amer M. Zeidan, MBBS, MHS

Blood (2020) 136 (Supplement 1): 29.

https://doi.org/10.1182/blood-2020-139428

Published: 2020

Journal Articles

Advanced Imaging and Targeted Myeloma Lesion Biopsies to Enhance Global Response Assessment and Evaluate Spatial Heterogeneity in Multiple Myeloma

Sabrina L. Browning, MD, Terri L. Parker, MD, Noffar Bar, MD, Tara Anderson, PA, Madhav V. Dhodapkar, MBBS, Stuart Seropian, MD, Alfred Ian Lee, MD PhD, Thomas Prebet, MD PhD, Stephanie Halene, MD, Mina L. Xu, MD, Elan Gorshein, DO, JD, MPH, Ashita Talsania, MCRP, MBBS, Wajih Zaheer Kidwai, MD, David H. Witt, MD, Victor Chang, MD, Andrew Lischuk, MD, Wei Wei, MD PhD, Andrew Haims, MD, Natalia Neparidze, MD

Blood (2020) 136 (Supplement 1): 20–22.

https://doi.org/10.1182/blood-2020-136478

Published: 2020

Journal Articles

Genetic Characteristics and Outcomes By Mutation Status in a Phase 3 Study of CPX-351 Versus 7+3 in Older Adults with Newly Diagnosed, High-Risk/Secondary Acute Myeloid Leukemia (AML)

R. Coleman Lindsley, MD PhD, Christopher J. Gibson, MD, H. Moses Murdock, BS, Richard M. Stone, MD, Jorge E. Cortes, MD, Geoffrey L. Uy, MD, Tara L. Lin, MD, Ellen K. Ritchie, MD, Thomas Prebet, MD PhD, Robert J. Ryan, MS, Stefan Faderl, MD, Jeffrey E. Lancet, MD

Blood (2019) 134 (Supplement_1): 15.

https://doi.org/10.1182/blood-2019-124500

Published: 2019

Journal Articles

Biomarker Modulation By Mivebresib (ABBV-075) +/- Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia

Gautam M. Borthakur, MD, Olatoyosi Odenike, MD, Ibrahim Aldoss, MD, David A. Rizzieri, MD, Thomas Prebet, MD PhD, Dimple A. Modi, PhD, Rujuta Joshi, Beibei Hu, Yan Sun, PhD, Johannes E. Wolff, MD, Brian A Jonas, MD PhD

Blood (2019) 134 (Supplement_1): 539.

https://doi.org/10.1182/blood-2019-126854

Published: 2019

Journal Articles

Olutasidenib (FT-2102), an IDH1m Inhibitor As a Single Agent or in Combination with Azacitidine, Induces Deep Clinical Responses with Mutation Clearance in Patients with Acute Myeloid Leukemia Treated in a Phase 1 Dose Escalation and Expansion Study

Blood (2019) 134 (Supplement_1): 231.

https://doi.org/10.1182/blood-2019-123920

Published: 2019

Journal Articles

The PRIME Trial: PARP Inhibition in IDH Mutant Effectiveness Trial. a Phase II Study of Olaparib in Isocitrate Dehydrogenase (IDH) Mutant Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome

Namrata S Chandhok, MD, Wei Wei, MD PhD, Ranjit Bindra, MD PhD, Stephanie Halene, MD, Yu Shyr, Jing Li, PhD, Michael Berens, PhD, Chris Karlovich, PhD, S. Percy Ivy, MD, Thomas Prebet, MD PhD

Blood (2019) 134 (Supplement_1): 3909.

https://doi.org/10.1182/blood-2019-129168

Published: 2019

Journal Articles

Clinical Outcomes of Patients (pts) with TP53-Mutated Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS): A Single Center Experience

Jan Philipp Bewersdorf, MD, Rory M Shallis, MD, Lohith Gowda, MD MRCP, Karl Hager, PhD, Nikolai A. Podoltsev, MD PhD, Steven D. Gore, MD, Thomas Prebet, MD PhD, Stephanie Halene, MD, Iris Isufi, MD, Francine M. Foss, MD, Scott F. Huntington, MD MPH, Tae Kon Kim, MD PhD, Manoj M Pillai, MD, Terri L Parker, MD, Natalia Neparidze, MD, Noffar Bar, MD, Stuart Seropian, MD, Alexa J. Siddon, MD, Amer M. Zeidan, MBBS, MHS

Blood (2019) 134 (Supplement_1): 5173.

https://doi.org/10.1182/blood-2019-127162

Published: 2019

Journal Articles

Isolated Trisomy 11 in Patients with Myeloid Malignancies - Is the Prognosis Not As Grim As Previously Thought?

Jan Philipp Bewersdorf, MD, Rory M Shallis, MD, Autumn Diadamo, BS, Lohith Gowda, MD, Nikolai A. Podoltsev, MD PhD, Steven D. Gore, MD, Thomas Prebet, MD PhD, Stephanie Halene, MD, Iris Isufi, MD, Francine M. Foss, MD, Scott F. Huntington, MD MPH, Tae Kon Kim, MD PhD, Manoj M Pillai, MD, Terri L Parker, MD, Natalia Neparidze, MD, Noffar Bar, MD, Stuart Seropian, MD, Alexa J. Siddon, MD, Amer M. Zeidan, MBBS, MHS

Blood (2019) 134 (Supplement_1): 5174.

https://doi.org/10.1182/blood-2019-127277

Published: 2019

Journal Articles

PARP Inhibitors Are Effective in IDH1/2 Mutant MDS and AML Resistant to Targeted IDH Inhibitors

Rana Gbyli, MS, Yuanbin Song, MD, Wei Liu, PhD, Yimeng Gao, PhD, Namrata S Chandhok, MD, Xiaoying Fu, MD, Xiaman Wang, MD PhD, Amisha Patel, MS, Ranjini Sundaram, PhD, Toma Tebaldi, PhD, Giulia Biancon, PhD, Anastasia Ardasheva, BS, Ashley Qin, Mukhtar Sadykov, MD, Padmavathi Mamillapalli, BS, Richard Flavell, PhD, Thomas Prebet, MD PhD, Ranjit Bindra, MD PhD, Stephanie Halene, MD

Blood (2019) 134 (Supplement_1): 4222.

https://doi.org/10.1182/blood-2019-130814

Published: 2019

Journal Articles

Ivo-Nivo: A Phase II Study of the IDH1 Inhibitor Ivosidenib (AG-120) in Combination with the Checkpoint Blockade Inhibitor Nivolumab for Patients with IDH1 Mutated Relapsed/Refractory AML and High Risk MDS

Namrata S Chandhok, MD, Wei Wei, MD, Stephanie Halene, MD, Thomas Prebet, MD PhD

Blood (2019) 134 (Supplement_1): 1374.

https://doi.org/10.1182/blood-2019-130033

Published: 2019

Journal Articles

Immune Checkpoint Inhibitor Therapy for Acute Myeloid Leukemia and Higher-Risk Myelodysplastic Syndromes: A Single-Center Experience

Rory M Shallis, MD, Jan Philipp Bewersdorf, MD, Lohith Gowda, MD, Nikolai A. Podoltsev, MD PhD, Thomas Prebet, MD PhD, Steven D. Gore, MD, Stephanie Halene, MD, Iris Isufi, MD, Francine M. Foss, MD, Scott F. Huntington, MD MPH, Tae Kon Kim, MD PhD, Manoj M Pillai, MD, Terri L Parker, MD, Natalia Neparidze, MD, Noffar Bar, MD, Stuart Seropian, MD, Amer M. Zeidan, MBBS, MHS

Blood (2019) 134 (Supplement_1): 1330.

https://doi.org/10.1182/blood-2019-127422

Published: 2019

NARROW

AML-MR Mutations Drive the Benefit of CPX-351 over 7+3 in the Pivotal Phase 3 AML Trial

Intensive Chemotherapy (IC) Followed By Oral Azacitidine (AZA) Maintenance Versus Venetoclax (VEN) Plus AZA for Patients (pts) with Acute Myeloid Leukemia (AML): Retrospective Analysis of an Electronic Medical Record (EMR) Database in the United States

Efficacy and Safety of Luspatercept Versus Epoetin Alfa in Erythropoiesis-Stimulating Agent (ESA)-Naive Patients (Pts) with Transfusion-Dependent (TD) Lower-Risk Myelodysplastic Syndromes (LR-MDS): Full Analysis of the COMMANDS Trial

Clonal Dynamics of Gene Mutations during Oral Azacitidine Maintenance Therapy in Patients with Acute Myeloid Leukemia (AML): Outcomes from the QUAZAR AML-001 Trial

Survival Outcomes for Patients in the QUAZAR AML-001 Trial Who Received Subsequent Therapy for Acute Myeloid Leukemia (AML) after Discontinuing Oral Azacitidine or Placebo

Molecular Features Associated with Response to Combination Therapy with Enasidenib (ENA) Plus Azacitidine (AZA) in Newly Diagnosed IDH2 -Mutated Acute Myeloid Leukemia (AML)

Olutasidenib (FT-2102) in Combination with Azacitidine Induces Durable Complete Remissions in Patients with mIDH1 Acute Myeloid Leukemia

Implementation of Inpatient Palliative Care Consultation Triggers and Its Impact on Healthcare Use in Patients with Relapsed/Refractory Acute Myeloid Leukemia

Characteristics and Clinical Outcome of Patients with Clonal Cytopenias of Undetermined Significance: A Large Retrospective Multi-Center International Study

Trial in Progress: Glad-AML - a Randomized, Phase 2 Trial of Glasdegib with Two Standard Decitabine Regimens for Older Patients with Newly-Diagnosed, Poor-Risk Acute Myeloid Leukemia

Advanced Imaging and Targeted Myeloma Lesion Biopsies to Enhance Global Response Assessment and Evaluate Spatial Heterogeneity in Multiple Myeloma

Genetic Characteristics and Outcomes By Mutation Status in a Phase 3 Study of CPX-351 Versus 7+3 in Older Adults with Newly Diagnosed, High-Risk/Secondary Acute Myeloid Leukemia (AML)

Biomarker Modulation By Mivebresib (ABBV-075) +/- Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia

Olutasidenib (FT-2102), an IDH1m Inhibitor As a Single Agent or in Combination with Azacitidine, Induces Deep Clinical Responses with Mutation Clearance in Patients with Acute Myeloid Leukemia Treated in a Phase 1 Dose Escalation and Expansion Study

The PRIME Trial: PARP Inhibition in IDH Mutant Effectiveness Trial. a Phase II Study of Olaparib in Isocitrate Dehydrogenase (IDH) Mutant Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome

Clinical Outcomes of Patients (pts) with TP53-Mutated Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS): A Single Center Experience

Isolated Trisomy 11 in Patients with Myeloid Malignancies - Is the Prognosis Not As Grim As Previously Thought?

PARP Inhibitors Are Effective in IDH1/2 Mutant MDS and AML Resistant to Targeted IDH Inhibitors

Ivo-Nivo: A Phase II Study of the IDH1 Inhibitor Ivosidenib (AG-120) in Combination with the Checkpoint Blockade Inhibitor Nivolumab for Patients with IDH1 Mutated Relapsed/Refractory AML and High Risk MDS

Immune Checkpoint Inhibitor Therapy for Acute Myeloid Leukemia and Higher-Risk Myelodysplastic Syndromes: A Single-Center Experience

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only